U.S. Patent Appn. Serial No. 10/008,955 Substitute Specification Submitted With Amendment and Response to Non-final Office Action dated October 12, 2010 In Response to Non-Final Office Action mailed July 9, 2010

## NATURAL KILLER CELL LINES AND METHODS OF USE

## ABSTRACT

This invention relates to a natural killer cell line termed NK-92 and to NK-92 cell lines that have been modified by transfection with a vector to confer advantageous properties. Additionally, the invention provides an NK-92 cell, an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves the effective cytotoxic activity. The invention provides a modified NK-92 cell line that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. In a significant embodiment, the cytokine is interleukin 2. The invention additionally provides a modified NK-92 cell line that is transfected with a vector that expresses a thymidine kinase gene. The invention further provides a modified NK-92 cell line that is transfected with a vector that expresses a  $\beta_2$  micrglobulin that has lost the ability to bind to T-cell receptors.